These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15763970)

  • 1. Recombinant activated factor VII in patients at high risk of bleeding.
    Kubisz P; Stasko J
    Hematology; 2004; 9(5-6):317-32. PubMed ID: 15763970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant activated factor VII (rFVIIa, NovoSeven).
    Agarwal MB; Patnaik M
    J Assoc Physicians India; 2005 Aug; 53():717-20. PubMed ID: 16398083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
    Mariani G; Konkle BA; Ingerslev J
    Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
    Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
    Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
    Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NovoSeven: mode of action and use in acquired haemophilia.
    Von Depka M
    Intensive Care Med; 2002 Oct; 28 Suppl 2():S222-7. PubMed ID: 12404090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
    Smith OP
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
    Kessler C
    Intensive Care Med; 2002 Oct; 28 Suppl 2():S228-34. PubMed ID: 12404091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety update on the use of recombinant activated factor VII in approved indications.
    Neufeld EJ; Négrier C; Arkhammar P; Benchikh el Fegoun S; Simonsen MD; Rosholm A; Seremetis S
    Blood Rev; 2015 Jun; 29 Suppl 1():S34-41. PubMed ID: 26073367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant activated factor VII: 30 years of research and innovation.
    Hedner U
    Blood Rev; 2015 Jun; 29 Suppl 1():S4-8. PubMed ID: 26073368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven).
    Mullighan CG; Rischbieth A; Duncan EM; Lloyd JV
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):347-51. PubMed ID: 15166922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall experience with NovoSeven.
    Négrier C; Lienhart A
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S19-24. PubMed ID: 10850559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
    Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
    Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.